Citius Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Citius Pharmaceuticals, Inc. (CTXR) reported Capital Expenditures Incurred but Not yet Paid of $28.40 million for the 12-month period ending 2024-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-12-23
- Citius Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $28.40M.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2024-09-30 | $28.40M 10-K · filed 2025-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |